Neuroscience
FDA rejects a new epilepsy drug from Valeant, GSK
FierceBiotech
02 December 2010
Read FierceBiotech article here
===
Earlier blog post on topic, from 12th August: here
===
- Will There Be Biotechs "emerging From The Rubble At Sandwich"?
Investors ready to craft new biotechs out of Pfizer's discards February 9, 2011 — 8:47am ET By John Carroll FierceBiotech Read the article...
- Top 10 Phase Iii Failures Of 2010
From FierceBiotech, an interesting report: Full article: Top 10 Phase III Failures of 2010...
- Business World: Gsk's Rare Diseases R&d Unit
From FierceBiotech: GSK launches new specialist unit to research and develop medicines for rare diseases Issued: Thursday 4 February 2010, London UK Read the full article...
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- Merck's Cladribine And Multiple Sclerosis
From FierceBiotech: Merck KGaA pulls ahead in hot oral MS drug race By John Carroll September 11, 2009 — 8:22am ET Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential...
Neuroscience
FDA Rejects Ezogabine
FDA rejects a new epilepsy drug from Valeant, GSK
FierceBiotech
02 December 2010
Read FierceBiotech article here
===
Earlier blog post on topic, from 12th August: here
===
- Will There Be Biotechs "emerging From The Rubble At Sandwich"?
Investors ready to craft new biotechs out of Pfizer's discards February 9, 2011 — 8:47am ET By John Carroll FierceBiotech Read the article...
- Top 10 Phase Iii Failures Of 2010
From FierceBiotech, an interesting report: Full article: Top 10 Phase III Failures of 2010...
- Business World: Gsk's Rare Diseases R&d Unit
From FierceBiotech: GSK launches new specialist unit to research and develop medicines for rare diseases Issued: Thursday 4 February 2010, London UK Read the full article...
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- Merck's Cladribine And Multiple Sclerosis
From FierceBiotech: Merck KGaA pulls ahead in hot oral MS drug race By John Carroll September 11, 2009 — 8:22am ET Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential...